About the Company
We do not have any company description for Atara Biotherapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Atara Biotherapeutics, Inc.
Atara Makes Second Try With FDA
Thousand Oaks-based immunotherapy company Atara Biotherapeutics Inc., which is attempting to develop drugs from a T-cell ...
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO ...
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq ...
This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of February 3, 2025 ...
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
Atara Biotherapeutics Announces Pricing of $16 Million Offering
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for ...
Atara Biotherapeutics, Inc. Is Being Investigated For ... - KRON4
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm News provided by ACCESSWIRE Feb 16, 2025, 11: ...
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law ...
Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm PRESS RELEASE ACCESS Newswire Feb. 4, 2025, 06:30 PM ...
Atara Biotherapeutics Announces First Quarter Financial Results and ...
Atara reported net income of $38.0 million, or $3.53 basic earnings per share and $3.50 diluted earnings per share, for the first quarter 2025, as compared to a net loss of $31.8 million, or $5.65 ...
Similar Companies
Loading the latest forecasts...